Peer-Reviewed Work

Publications

150+ peer-reviewed publications on AI in dermatology, AI in melanoma, cutaneous oncology, oncodermatology, and immune-mediated skin disease. 4,500+ citations. Full list on Google Scholar.

Melanoma recurrence ROC curves — AUROC 0.845 internal, 0.812 external
Melanoma ML ROC curves — AUROC 0.845 internal, 0.812 external · Wan et al., npj Precision Oncology 2022
Cutaneous irAE incidence rate ratios
Cutaneous irAE incidence rate ratios · Wongvibulsin, …, Semenov, JAAD 2022
J Am Acad Dermatol 2026

Risk and protective factors for uveal melanoma: A population-level analysis

Lu A, …, Semenov YR et al.

npj Digital Medicine 2025

Academia loses its grip on digital health solutions as innovation in artificial intelligence shifts towards industry

Hijaz B, …, Semenov YR et al.

Lancet Oncology 2024

Multi-organ immune-related adverse events associated with immune checkpoint inhibitor therapy

Wan G, …, Semenov YR et al.

J Immunother Cancer (JITC) 2024

Defining D-irAEs: consensus-based disease definitions for the diagnosis and severity grading of dermatologic immune-related adverse events

Chen ST*, Semenov YR*, Gabel CK, Leventhal JS, … et al. (*co-first)

J Am Acad Dermatol 2024

Development and validation of time-to-event models to predict distant recurrence of localized melanoma

Wan G, …, Semenov YR et al.

Briefings in Bioinformatics 2024

SpatialCells: automated profiling of tumor microenvironments with spatially resolved multiplexed single-cell data

Wan G, …, Semenov YR et al.

J Am Acad Dermatol 2023

Cutaneous immune-related adverse events are associated with improved survival in patients with melanoma treated with immune checkpoint inhibitors

Wan G, …, Semenov YR et al.

JAMA Dermatology 2022

Association of cutaneous immune-related adverse events with increased survival in patients treated with anti-PD-1 and anti-PD-L1 therapy

Tang T, …, Semenov YR et al.

J Am Acad Dermatol 2022

Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors

Wongvibulsin S, Pahalyants V, …, Semenov YR et al.

Nature Medicine 2022

Germline variants associated with immune checkpoint inhibitor toxicity

Groha S, Alaiwi SA, …, Semenov YR et al.

npj Precision Oncology 2022

Prediction of early-stage melanoma recurrence using clinical and histopathologic features

Wan G, Nguyen N, Liu F, …, Semenov YR et al.

View All 150+ Publications on Google Scholar